Pushing for top spot in Big Pharma, AbbVie lands a key approval for its blockbuster Skyrizi
AbbVie just scored another win in its campaign to make Skyrizi one of the top blockbusters in the portfolio while pushing the Big Pharma to the top of the industry list of money makers as their cash cow Humira faces biosimilar competition in January.
Earlier this year the FDA’s OK came through on psoriatic arthritis, following the maiden approval for psoriasis. And today we learned that the agency has stamped its approval to expand the label to include Crohn’s disease.
Along with Rinvoq and Venclexta, analysts have pegged the IL-23 drug as a key product that will drive AbbVie’s revenue to $65.7 billion by 2028. If it’s accurate — and these projections have a way of going sideways — that would put AbbVie on top of Roche and J&J. AbbVie’s continued success at the FDA underscores the effectiveness of CEO Rick Gonzalez’s campaign to remake AbbVie after taking the helm of the Abbott spinout.
Skyrizi earned close to $3 billion last year and Gonzalez has pegged 2025 sales at $7.5 billion.
“We are proud to offer the first new treatment option in six years for moderately to severely active CD, which may provide patients with a meaningful level of endoscopic improvement,” said Thomas Hudson, the chief scientific officer at AbbVie. “With more than 30 ongoing or planned trials in inflammatory bowel disease, AbbVie is committed to advancing the standards of care for patients by exploring and investing in research for those living with immune-mediated, gastroenterological conditions.”
“In both the induction and maintenance clinical trials, a significantly greater number of adult patients saw few or no symptoms and a meaningful reduction of visible signs of intestinal inflammation, compared to placebo,” said Marla Dubinsky, chief, division of pediatric gastroenterology for the Mount Sinai Health System.